Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a randomised, phase 3 study evaluating atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, Enrique, Bamias, Aristotelis, Galsky, Matthew D., Kikuchi, Eiji, Davis, Ian D., Arranz, José Ángel, Rezazadeh Kalebasty, Arash, Garcia del Muro, Xavier, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Puente, Javier, Li, Jian-Ri, Bernhard, Sandrine, Nicholas, Alan, Telliez, Julie, De Santis, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632822/
https://www.ncbi.nlm.nih.gov/pubmed/37954037
http://dx.doi.org/10.1016/j.euros.2023.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632822/
https://www.ncbi.nlm.nih.gov/pubmed/37954037
http://dx.doi.org/10.1016/j.euros.2023.10.002

Ejemplares similares